Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant747 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,431 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01690598 | Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | completed | Phase 1 / Phase 2 | 22 | Vejle HospitalOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT00343044 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | completed | Phase 2 | 40 | Benaroya Research InstituteOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00072566 |
| Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer |
| completed |
| Phase 2 |
| 70 |
| National Cancer Institute (NCI)NIH |
| 1 |
| May 12, 2015 |
| clinicaltrials |
| NCT01196741 | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer(SaPPrOC) | completed | Phase 2 / Phase 3 | 107 | University College, LondonOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT00039585 | Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00267696 | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00127920 | Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients | completed | Phase 2 | 20 | Gynecologic Oncology AssociatesOTHER | 1 | Mar 10, 2015 | clinicaltrials |
| NCT00345540 | Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer | completed | Phase 2 | 15 | Cellectar Biosciences, Inc.INDUSTRY | 1 | Mar 10, 2015 | clinicaltrials |
| NCT01227928 | Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | completed | Phase 2 | 145 | GlaxoSmithKlineINDUSTRY | 4 | Mar 3, 2015 | clinicaltrials |
| NCT00090610 | Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer | completed | Phase 2 | 150 | Duke UniversityOTHER | 1 | Feb 25, 2015 | clinicaltrials |
| NCT01047891 | Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer(TRIAS 2009) | completed | Phase 2 | 174 | JSehouliOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT01196559 | Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 44 | The Catholic University of KoreaOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT01815528 | Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer | completed | Phase 2 | 2 | JSehouliOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT00388037 | Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT00507741 | Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) | completed | Phase 2 | 49 | EndocyteINDUSTRY | 0 | Jan 7, 2015 | clinicaltrials |
| NCT00722592 | Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)(PRECEDENT) | completed | Phase 2 | 162 | EndocyteINDUSTRY | 0 | Jan 7, 2015 | clinicaltrials |
| NCT00390611 | Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer | completed | Phase 2 | 85 | SCRI Development Innovations, LLCOTHER | 1 | Dec 22, 2014 | clinicaltrials |
| NCT02004093 | A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer | completed | Phase 2 | 149 | Hoffmann-La RocheINDUSTRY | 9 | Dec 4, 2014 | clinicaltrials |
| NCT00751205 | Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) | completed | Phase 2 | 150 | BayerINDUSTRY | 6 | Oct 28, 2014 | clinicaltrials |
| NCT00928642 | Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 8 | Henry M. Jackson Foundation for the Advancement of Military MedicineOTHER | 1 | Oct 21, 2014 | clinicaltrials |
| NCT00868192 | Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | completed | Phase 2 | 38 | Washington University School of MedicineOTHER | 1 | Oct 20, 2014 | clinicaltrials |
| NCT01481701 | A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma | completed | Phase 2 | 90 | Jules Bordet InstituteOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT01834469 | Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients(OV-AP-ICG-IV) | completed | Phase 1 / Phase 2 | 10 | Jules Bordet InstituteOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00477386 | Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | Indiana UniversityOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01104675 | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | completed | Phase 2 | 64 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Aug 6, 2014 | clinicaltrials |
| NCT01163552 | Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity | completed | Phase 2 | 5 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jun 13, 2014 | clinicaltrials |
| NCT00245102 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | completed | Phase 2 | 147 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00003449 | Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 35 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183794 | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00083122 | Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00093496 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
| NCT00126542 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00170677 | Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer | completed | Phase 2 | 194 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 14, 2014 | clinicaltrials |
| NCT00841191 | A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors | completed | Phase 1 / Phase 2 | 84 | Centocor, Inc.INDUSTRY | 5 | May 14, 2014 | clinicaltrials |
| NCT00436644 | Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | completed | Phase 2 | 18 | Mayo ClinicOTHER | 1 | Apr 16, 2014 | clinicaltrials |
| NCT00086892 | Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 5 | Feb 14, 2014 | clinicaltrials |
| NCT00087087 | Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Feb 14, 2014 | clinicaltrials |
| NCT00504257 | Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma | completed | Phase 2 | 45 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT01639885 | Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer(CHIP) | completed | Phase 1 / Phase 2 | 15 | Leiden University Medical CenterOTHER | 1 | Jan 7, 2014 | clinicaltrials |
| NCT00096239 | CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00025441 | Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors | completed | Phase 2 | — | Societe Internationale d'Oncologie PediatriqueOTHER | 3 | Dec 4, 2013 | clinicaltrials |
| NCT01079832 | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2013 | clinicaltrials |
| NCT00617773 | Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 31 | Recepta BiopharmaINDUSTRY | 1 | Nov 26, 2013 | clinicaltrials |
| NCT00721890 | Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma(DBGT-OC-CR) | completed | Phase 2 | 16 | CHU de Quebec-Universite LavalOTHER | 1 | Oct 24, 2013 | clinicaltrials |
| NCT00526149 | BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors | completed | Phase 2 | 76 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Oct 7, 2013 | clinicaltrials |
| NCT00677079 | Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 12 | SanofiINDUSTRY | 1 | Oct 1, 2013 | clinicaltrials |
| NCT00831636 | A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | Clavis PharmaINDUSTRY | 2 | Sep 13, 2013 | clinicaltrials |
| NCT00698451 | A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers | completed | Phase 2 | 54 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Sep 6, 2013 | clinicaltrials |
| NCT00004876 | Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer | completed | Phase 2 | 30 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00006942 | Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jun 10, 2015source: clinicaltrials